Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px

Deals > All

Total search results: 9816 | Ordered by Date (descending)
next pagenext page 1 2 3 4 ... 97 98 99  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cytena–SEVERAL: investment, 201903 financing round Series A €3.m from HTGF + two private investors 2019-03-26
Evotec–Mark Foundation: investment, 201903–202102 research funding for two years €na by Mark Foundation with potential financial returns 2019-03-26
Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine 2019-03-26
Menarini–Curetis: molecular diagnostics, 201903– distribution excl long-term of Unyvero platform + cartridges in Europe by Menarini Diagnostics 2019-03-26
Synerkine Pharma–SEVERAL: investment, 201903 financing round Series A €3.3m from Thuja Capital + private investor + company founders 2019-03-25
Synerkine Pharma–Thuja Capital: investment, 201903 financing round Series A totalling €3.3m incl Thuja Capital + private investor + company founders 2019-03-25
Brammer Bio–Thermo Fisher: investment, 201903– acquisition $1.7b in cash from Ampersand Capital Partners + Founders ANNOUNCED 2019-03-24
Exscientia–Edelman: public relations, 201803 service existent by Edelman PR 2019-03-22
Hookipa–SEVERAL: investment, 201903– IPO $84m+$12.6m with 6m+900k shares common stock at Nasdaq Global Select Market 2019-03-22
Celgene–Exscientia: drug discovery software, 201903–202203 collab $25m upfront + milestones + royalties 3y AI drug discovery partnership 2019-03-21
Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF 2019-03-21
United Kingdom (govt)–Cambridge Cancer Genomics: personalised immuno-oncology, 201903– collab long-term of Genomics England + CCG.ai 2019-03-21
Verona Pharma–ICR: public relations, 201903 service existent by ICR in US 2019-03-21
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai 2019-03-20
NeoPhore–Optimum Strategic Communications: public relations, 201903 service existent by Optimum 2019-03-20
Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) 2019-03-20
Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares 2019-03-20
Oncimmune–Consilium: public relations, 201903 service existent by CSC 2019-03-19
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Mogrify–United Kingdom (govt): grant, 201903 Innovate UK funding £420k to use big data analysis to advance cell therapies 2019-03-18
Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp 2019-03-14
Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects 2019-03-14
Metrion Biosciences–o2h: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Metrion Biosciences–SEVERAL: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications 2019-03-13
Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri 2019-03-12
Biogen–Fujifilm: investment, 201903– acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark 2019-03-12
BMS–Biocartis: molecular companion diagnostics, 201903– collab Idylla MSI testing with cancer immunotherapies 2019-03-12
Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors 2019-03-12
AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies 2019-03-11
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test 2019-03-08
Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments 2019-03-07
SOM Biotech–SEVERAL: investment, 201903 financing round €7m led by European family holding 2019-03-07
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
NovaGo Therapeutics–Neurimmune: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor + strategic partner Neurimmune 2019-03-04
NovaGo Therapeutics–Pureos Bioventures: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor Pureos Bioventures 2019-03-04
NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune 2019-03-04
Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TreeFrog Therapeutics–SEVERAL: grant, 201903 non-dilutive funding €600k from Nouvelle-Aquitaine Region + Bpifrance + French Ministry of Research 2019-03-01
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation 2019-02-28
Sarepta–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene 2019-02-28
CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio 2019-02-27
Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America 2019-02-27
Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market 2019-02-27
MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management 2019-02-27
MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc 2019-02-27
MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors 2019-02-27
MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors 2019-02-27
MeiraGTx–SEVERAL: investment, 201902 private placement $80m with 5.8m ordinary shares at $13.8/share led by JJDC Inc 2019-02-27
Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck 2019-02-27
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Hookipa–Invus Group: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Invus 2019-02-26
Hookipa–Redmile Group: investment, 201902 financing round Series D totalling €33.2m incl new + lead investor Redmile Group 2019-02-26
Hookipa–Samsara BioCapital: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Samsara BioCapital 2019-02-26
Hookipa–SEVERAL: investment, 201902 financing round Series D €33.2m ($37.4m) led by Redmile Group + incl Invus + Samsara Capital et al. 2019-02-26
Samsara Therapeutics–Apollo Ventures: investment, 201902 seed financing round totalling €1m incl lead investor Apollo Ventures 2019-02-26
Samsara Therapeutics–Evotec: medicinal chemistry, 201902 supply service existent compound optimisationn by Evotec 2019-02-26
Samsara Therapeutics–SEVERAL: investment, 201902 seed financing round €1m led by Apollo Ventures 2019-02-26
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Mobidiag–Consilium: public relations, 201902 service existent by CSC 2019-02-25
Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche 2019-02-25
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Roche: investment, 201902– acquisition $4.3b cash tender offer for all shares at $114.5/share ANNOUNCED 2019-02-25
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
Aidence–ABP (NL): investment, 201902 financing round Series A totalling €10m incl lead investor Inkef Capital 2019-02-20
Aidence–Rabo Ventures: investment, 201902 financing round Series A totalling €10m incl co-investor Rabo Ventures 2019-02-20
Aidence–SEVERAL: investment, 201902 financing round Series A €10m led by Inkef Capital + co-investor Rabo Ventures et al 2019-02-20
Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner 2019-02-20
BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund 2019-02-20
BiomX–MacDougall Biomedical Communications: public relations, 201902 service existent by MacDougall 2019-02-20
BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al 2019-02-20
BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan 2019-02-20
Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totallling €20m incl co-lead investor Inkef Capital 2019-02-20
Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totallling €20m incl co-lead investor Gilde Healthcare 2019-02-20
Calypso Biotech–JnJ: investment, 201902 financing round Series A totallling €20m incl co-investor JnJ Innovation JJDC 2019-02-20
Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totallling €20m incl co- + founding investor M Ventures 2019-02-20
Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital 2019-02-20
Evotec–Helmholtz: antibiotics, 201902– collab development with initial focus on cystobactamids with Helmholtz HZI Braunschweig 2019-02-20
Mogrify–24Haymarket: investment, 201902 seed financing round totalling $3.7m incl co-investor 24Haymarket 2019-02-20
next pagenext page 1 2 3 4 ... 97 98 99  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top